Emerging in the field of weight management therapy, retatrutide represents a distinct strategy. Beyond many available medications, retatrutide functions as a twin agonist, concurrently affecting both GLP peptide-1 (GLP-1) and glucose-sensitive insulinotropic hormone (GIP) sensors. The concurrent activation fosters various helpful effects, including